about
Comparison of human hepatoma HepaRG cells with human and rat hepatocytes in uptake transport assays in order to predict a risk of drug induced hepatotoxicityHepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation.Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion.Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening.Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver.Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse.Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.Pleiotropic effects of glitazones: a double edge sword?Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4α transduction.Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicityDrug-induced mitochondrial toxicity.Minimising the potential for metabolic activation in drug discovery.Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump.Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.Drug metabolite profiling and elucidation of drug-induced hepatotoxicity.Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.Integrative toxicoproteomics implicates impaired mitochondrial glutathione import as an off-target effect of troglitazoneTechnical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP).Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes.Rapid LC-MS drug metabolite profiling using microsomal enzyme bioreactors in a parallel processing format.Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity.Idiosyncratic reactions and metabolism of sulfur-containing drugs.Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Role of Multidrug Resistance Protein 3 in Antifungal-Induced Cholestasis.Analysis of PPAR-α/γ Activity by Combining 2-D QSAR and Molecular Simulation.The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes.Cytotoxicity of thiazolidinedione-, oxazolidinedione- and pyrrolidinedione-ring containing compounds in HepG2 cells.Synthesis of tryptoline-3-carboxylic Acid derivatives a novel antidiabetic agentEditorial: Closing sale of innovative treatment options for the treatment of diabetes and metabolic disorders?Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers.Assessing health risks from multiple environmental stressors: Moving from G×E to I×E.SAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated ReceptorγActivators: A Perspective
P2860
Q28487995-8027AE6B-47E6-4D4C-B0F9-09E0500B0CE4Q33574904-FB8A09C1-3685-40B2-8B43-332B8F6ECA4BQ33742713-74E21C2A-24EC-427B-B1E2-5565C49FC37CQ33961458-A12796C1-083F-4B16-BE6A-A10D6CA21BB0Q34044936-58D07242-3AEE-4AC4-8D88-EF53B8773435Q34235817-7AD69F9A-15D6-41C5-A8AB-D7348308B6DBQ34294773-7E6C3668-F405-408C-95F2-C30D092A7702Q34471194-5EFB96C7-6B22-4F5D-BC9D-95CF2772046FQ35025858-004C3703-A7DF-4A8C-8E65-53C5FC9C4A7FQ35665145-DE7D5687-1407-4ABE-8940-8BD1B22E3DD9Q35781894-AF6EA6B0-4B6E-45D1-B05D-96D9D7355D54Q36544880-E5FE6F8B-A8D5-473D-8104-2A7871EA6C2EQ36572637-B9255504-13AB-4B3C-9E6E-5B3BD621CC8BQ36689081-52FD63A4-508E-4AED-BE71-06DD2AC0E066Q36748508-F5181761-B9A3-4F72-9B4F-5561C2569A81Q36835826-A14F11D1-DE42-4F7B-A981-FB44BC37E6FAQ36943606-1F75A6B2-E433-4D8B-B4BE-4D8EE52CFA81Q37247744-4046137E-096B-46D7-AC19-2C87559BEDB4Q37378080-510D484E-3C6C-4314-A724-428E58FD8B97Q37399040-A35C0DE4-9F5F-4109-9F11-09AD930BEFF5Q37480700-238E3787-61A7-49DE-BA6D-FF2027620B4CQ37638755-0FAA8F39-5131-4724-8018-5DF5721FC79CQ37950014-DCE0045E-702C-446F-A20C-7300AC197741Q37991021-9613DDBF-1AD7-4178-99FC-E3CC2B9183BEQ38151571-B636979F-5AC7-4CC6-8FCA-78F4D8A895E5Q38684505-8F1472B8-F708-4500-965A-C8C9B3ED67A4Q38775583-75F48C15-56C5-4D4C-95B8-6C6FB9CF79D6Q39535351-BAB3AB1E-B0C1-4EE5-B6CC-BF88E95FE1EEQ40059036-BACAE307-279D-4609-9A3E-7643AD390D6BQ41451544-5474CF1D-E432-4368-A62F-FC7ED40510E9Q42155492-84EC5B89-03C1-4DEE-860D-92D349A73485Q42416649-26BF53F8-65AA-46B7-8643-A69C04AB52AFQ44160577-D8BFAFCE-0550-433F-AEDA-BBE0F36FA8A9Q52648322-B6A4B93A-FA9A-4815-AF7A-5AA20FC9F2D0Q58919671-4B9CA100-13B4-4C7F-8B6A-941E6484DA3E
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mechanisms of troglitazone hepatotoxicity.
@ast
Mechanisms of troglitazone hepatotoxicity.
@en
type
label
Mechanisms of troglitazone hepatotoxicity.
@ast
Mechanisms of troglitazone hepatotoxicity.
@en
prefLabel
Mechanisms of troglitazone hepatotoxicity.
@ast
Mechanisms of troglitazone hepatotoxicity.
@en
P356
P1476
Mechanisms of troglitazone hepatotoxicity.
@en
P2093
Martyn T Smith
P304
P356
10.1021/TX034033E
P577
2003-06-01T00:00:00Z